Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Porcine-collagen hydrolysate is a dietary supplement produced by the enzymatic hydrolysis of collagen derived from pigs. It is composed of a mixture of bioactive peptides. While collagen hydrolysates are commonly marketed for skin, bone, and joint health, this specific porcine-derived formulation was evaluated for its effects on glucose metabolism and cardiometabolic risk markers in overweight and obese individuals. In a randomized, placebo-controlled trial (NCT05282641), daily consumption of 10g for four weeks failed to improve interstitial glucose concentrations and was associated with slight increases in glycemic variability, fasting insulin, and HOMA-IR, indicating it does not significantly improve glucose metabolism in this population.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on porcine-collagen hydrolysate.